|
KMID : 1137020180290030035
|
|
Journal of Gynecologic Oncology
2018 Volume.29 No. 3 p.35 ~ p.35
|
|
|
Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients
|
|
Yang Bingyi
Xie Liying
Zhang Hongwei
Zhu Qin
Du Yan
Luo Xuezhen
Chen Xiaojun
|
|
|
Abstract
|
|
|
Objective: Our previous study showed that insulin resistance (IR) was related to endometrial hyperplasia as well as endometrial cancer. But the exact impact of IR on fertility-sparing treatment in endometrial hyperplasic disease is unclear. This study investigated how IR affects fertility-sparing treatment in endometrial atypical hyperplasia (EAH) patients.
Methods: The 151 EAH patients received fertility-sparing treatment were retrospectively investigated. All patients received high-dose progestin combined with hysteroscopy. Therapeutic effects were evaluated by hysteroscopy every 3 months during the treatment.
Results: The median age was 33.0 years old (range, 21?54 years old). Sixty-one patients (40.4%) were insulin resistant. Three patients were excluded from the analysis because they chose hysterectomy within 3 months after initiation of progestin treatment. The 141 out of 148 (95.3%) patients achieved complete response (CR). No difference was found in cumulative CR rate between those with or without IR (90.2% vs. 95.6%, p=0.320). IR significantly affected therapeutic duration to achieve CR (8.1±0.5 months with IR vs. 6.1±0.4 months without IR, p=0.004). Overweight (body mass index [BMI]≥25 kg/m2) was associated with higher risk of treatment failure (odds ratio=5.61; 95% confidence interval=1.11?28.35; p=0.040) and longer therapeutic duration to achieve CR (7.6±0.5 months vs. 6.3±0.4 months, p=0.019). EAH patients with both IR and overweight (IR+BMI+) had the longest therapeutic time compared with other patients (8.8±0.6 months vs. 5.6±0.7, 6.3±0.4, and 6.4±0.8 months for IR?BMI+, IR?BMI?, and IR+BMI?, respectively, p=0.006).
Conclusion: IR and overweight were associated with longer therapeutic duration in EAH patients receiving progestin-based fertility-sparing treatment.
|
|
|
KEYWORD
|
|
|
Endometrial Hyperplasia, Conservative Treatment, Overweight, Insulin Resistance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|